Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer

Journal of Clinical Oncology

Volumn 20, Issue 19, 2002, Pages 3992-3998

  Iwashyna, Theodore J ^a   Lamont, Elizabeth B ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COLON CARCINOMA; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; SAMPLING; SCORING SYSTEM; TIME; TREATMENT OUTCOME;

EID: 0036789418     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.083     Document Type: Article

References (66)

1. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant treatment of resected colon carcinoma. N Engl J Med 322:353-358, 1990
2. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
3. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
4. Midgley RSJ, Kerr DJ: Colorectal cancer. Lancet 353:391-399, 1999
5. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy for large-bowel carcinoma: An evaluation of levamisole and the combination of fluorouracil. J Clin Oncol 7:1447-1456, 1989
6. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
7. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
8. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
9. Ries LAG, Kosary CL, Hankey BF, et al: SEER Cancer Statistics Review, 1973-1994. Bethesda, MD, National Cancer Institute, NIH publication 97-2789, 1997
10. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, et al: Patients' willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision-participation. Soc Sci Med 32:35-42, 1991
11. Verheggen FW, Nieman F, Jonkers R: Determinants of patient participation in clinical studies requiring informed consent: Why patients enter a clinical trial. Patient Educ Couns 35:111-125, 1998
12. Penman DT, Holland JC, Bahna GF, et al: Informed consent for investigational chemotherapy: Patients' and physicians' perceptions. J Clin Oncol 2:849-855, 1984
13. McCusker J, Wax A, Bennett JM: Cancer patient accessions into clinical trials. Am J Clin Oncol 5:227-236, 1982
14. Goodwin JS, Hunt WC, Humble CG, et al: Cancer treatment protocols: Who gets chosen? Arch Intern Med 148:2258-2260, 1988
15. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999
16. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878-1886, 2000
17. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887-1892, 2000
18. Feinstein AR: An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 99:544-550, 1983
19. Horwitz RI: The experimental paradigm and observational studies of cause-effect relationships in clinical medicine. J Chronic Dis 40:91-99, 1987
20. Horwitz RI, Feinstein AR: The application of therapeutic-trial principles to improve the design of epidemiologic research: A case-control study suggesting that anticoagulants reduce mortality in patients with myocardial infarction. J Chronic Dis 34:575-583, 1981
21. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
22. Nattinger AB, McAuliffe TL, Schapira MM: Generalizability of the Surveillance, Epidemiology, and Endq Results registry population: Factors relevant to epidemiologic and health care research. J Clin Epidemiol 50:939-945, 1997
23. Zippin C, Lum D, Hankey BF: Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute. Cancer 76:2343-2350, 1995
24. Hatten J: Medicare's common denominator: The covered population. Health Care Financ Rev 2:53-64, 1980
25. Lamont EB, Lauderdale DS, Schilsky RL, et al: Construct validity of Medicare chemotherapy claim: The case of 5FU. Med Care 40:201-211, 2002
26. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
27. Deyo RA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: A response. J Clin Epidemiol 46:1081-1082, 1993
28. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
29. Zhang JX, Iwashyna TJ, Christakis NA: The impact of alternative lookback periods and sources of information on Charlson comorbidity adjustment in Medicare claims. Med Care 37:1128-1139, 1999
30. Roetzheim RG, Pal N, Gonzalez EC, et al: Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 90:1746-1754, 2000
31. Dominitz JA, Samsa GP, Landsman P, et al: Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 82:2312-2320, 1988
32. Mor V, Guadagnoli E, Silliman RA, et al: Influence of old age, performance status, medical and psychological status on management of cancer patients, in Yancik R, Yates J (eds): Cancer in the Elderly (ed 1). New York, Springer, 1989
33. Ball JK, Alixhauser A: Treatment differences between blacks and whites with colorectal cancer. Med Care 34:970-984, 1996
34. Tropman SE, Hatzell T, Paskett E, et al: Colon cancer treatment in rural North and South Carolina. Cancer Detect Prev 23:428-434, 1999
35. Goodwin JS, Hunt WC, Key CR, et al: The effect of marital status on stage, treatment, and survival of cancer patients. JAMA 258:3125-3130, 1987
36. Hodgson DC, Fuchs CS, Ayanian JZ: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93:501-515, 2001
37. Hatzell TA, Ricketts TC, Tropman SE, et al: Rural physicians' understanding of the state-of-the-art in breast, colon and rectum cancer treatment. Cancer Causes Control 10:261-267, 1999
38. Boyd C, Zhang-Salomons JY, Groome PA, et al: Associations between community income and cancer survival in Ontario, Canada, and the United States. J Clin Oncol 17:2244-2255, 1999
39. Monnet E, Boutron MC, Faivre J, et al: Influence of socioeconomic status on prognosis of colorectal cancer: A population-based study in Cote D'Or, France. Cancer 72:1165-1170, 1993
40. Mayberry RM, Coates RJ, Hill HA, et al: Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst 87:1686-1693, 1995
41. Lee AJ, Baker CS, Gehlbach S, et al: Do black elderly Medicare patients receive fewer services? An analysis of procedure use for selected patient conditions. Med Care Res Rev 55:314-333, 1998
42. Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349-357, 2002
43. Rosenbaum PR, Rubin DB: Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516-524, 1984
44. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1984
45. Rosenbaum PR, Rubin DB: Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33-38, 1985
46. Rubin DB, Thomas N: Matching using estimated propensity scores: Relating theory to practice. Biometrics 52:249-264, 1996
47. Smith HL: Matching with multiple controls to estimate treatment effects in observational studies, in Raferty AE (ed): Sociological Methodology 1997. Oxford, Basil Blackwell, 1997, pp 325-353
48. Christakis NA, Iwashyna TJ: The health impact on families of healthcare: A matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. Soc Sci Med (in press)
49. Earle CC, Tsai JS, Gelber RD, et al: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 19:1064-1070, 2001
50. Connors AF Jr, Speroff T, Dawson NV, et al: The effectiveness of right heart catheterization in the initial care of critically in patients: SUPPORT Investigators. JAMA 276:889-897, 1996
51. Polanczyk CA, Rohde LE, Goldman L, et al: Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: An observational study. JAMA 286:309-314, 2001
52. Gum PA, Thamilarasan M, Watanabe J, et al: Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 286:1187-1194, 2001
53. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285:430-436, 2001
54. Dehejia RH, Wahba S: Causal effects in nonexperimental studies: Reevaluating the evaluation of training programs. J Am Stat Assoc 94:1053-1062, 1999
55. Smith JA, Todd PE: Reconciling conflicting evidence on the performance of propensity-score matching methods. Am Econ Rev 91:112-118, 2001
56. Lin DY, Wei LJ: The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84:1074-1078, 1989
57. Heckman JJ, Ichimura H, Todd PE: Matching as an econometric evaluation estimator. Rev Econ Stud 65:261-294, 1998
58. Ichimura H, Taber C: Propensity-score matching with instrumental variables. Am Econ Rev 91:119-124, 2001
59. Fisher ES, Barton JA, Malenka DJ, et al: Overcoming potential pitfalls in the Medicare data for epidemiologic research. Am J Public Health 80:533-546, 1990
60. Fisher ES, Whaley FS, Krushat M, et al: The accuracy of Medicare's hospital claims data: Progress has been made, but problems remain. Am J Public Health 82:243-248, 1992
61. Iezzoni LI: Risk Adjustment for Measuring Health Outcomes (ed 2). Chicago, IL, Health Administration Press, 1997
62. Lauderdale DS, Furner SE, Miles TP, et al: Epidemiologic uses of Medicare data. Epidemiol Rev 15:319-327, 1993
63. Romano PS, Mark DH: Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care 32:81-90, 1994
64. Roos LL, Sharp SM, Cohen MM: Comparing clinical information with claims data: Some similarities and differences. J Clin Epidemiol 44:881-888, 1991
65. Roos LL, Stranc L, James RC, et al: Complications, comorbidities, and mortality: Improving classification and prediction. Health Serv Res 32:229-238, 1997
66. Kohn LT, Corrigan JM, Donaldson MS: To Err Is Human: Building a Safer Health System. Washington, DC. National Academy Press, 2000